Rune is actively seeking investors at present to accelerate its product development pipeline through at a faster rate.
Royalties ensure future revenue but there is now a funding gap of around 2 years prior to which sales will only grow slowly without funding support.
We will consider funds for equity, loan funding or active development partnering.
Rune has low risk but high return product opportunities. A strong case can be made for investment funding into a satellite R&D facility for an NCE-focussed small pharma to de-risk it’s R&D Portfolio.
